anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Countries in Europe and around the world have taken varying approaches to their policies on COVID-19 vaccination for children. The low risk of severe illness from COVID-19 means that even small risks from vaccination warrant careful consideration. Vaccination appears to result in a decreased risk of severe illness including the paediatric multi-system inflammatory syndrome known to be associated with COVID-19. These risks have already decreased significantly with the emergence of the Omicron variant and its subvariants, and due to widespread population immunity through previous infection. There is a relatively high risk of myocarditis following second doses of mRNA vaccines in adolescent males, although the general course of this condition appears mild.   Conclusion: COVID-19 vaccination only provides a transient reduction in transmission. Currently, insufficient evidence exists to determine the impact of vaccination on post-acute COVID syndromes in children, which are uncommon. What is Known: • Vaccines against COVID-19 have significantly reduced morbidity and mortality around the world. • Whilst countries have universally recommended vaccines for adults and continue to recommend them for vulnerable populations, there has been more variability in recommendations for children. What is New: • In the setting of near universal existing immunity from infection, the majority of the initial benefit in protecting against severe illness has been eroded. • The risks of myocarditis following mRNA vaccination for children is low, but an important consideration given the modest benefits.
The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
PROBLEM TO BE SOLVED: To obtain a water-based composition which is applied to the skin and oral cavity, stably contains an oil-soluble substance and a peptide and is highly biocompatible and safe to the skin and the mucous membrane of oral cavity. SOLUTION: One or more kinds of oil-soluble substances or peptides are selected, included in a cyclodextrin polymer tube and compounded. The oil- soluble substance is e.g. a chain hydrocarbon, higher aliphatic alcohol, higher fatty acid, terpenoid, steroid, oil-soluble vitamin, prostaglandin, phospholipid, sphingolipid, oil soluble dye or ultraviolet-absorber. The peptide is e.g. a physiologically active peptide such as hydrolyzed product of skin-constituting protein, peptide hormone, interleukin, epidermal proliferation factor or fibroblast growth factor.
PURPOSE:To obtain an ethanol metabolism promoter containing extract of an Acathopanax (EZO UKOGI) by water or polar organic solvent as an active ingredient, capable of lowering ethanol amount in blood after drinking an alcohol by administration after drinking an alcohol and being safe to long term administration without side reactions. CONSTITUTION:The aimed promoter containing an extract obtained by extracting an Acathopanax (EZO UKOGI) with water or polar organic solvent (e.g. methanol, ethanol, etc.) as an active ingredient. The Acathopanax is a medicine plant of Araliaceae which glows in crows in east north part of Chinese and readily available. The extract of Acathopanax is obtained by drying the Acathopanax in a dryer, normally at 60-63 deg.C for 15-20hr and pulverizing the dried Acathopanax and extracting the resultant powder. Drink agent obtained by sealing the extract in bial is preferably taken at an amount of 1-3g as pure extract/ adult day before at least 60-100min when drunk.
PURPOSE:To prevent the bending and broken yarns in melt spinning, by incorporating bis(p-chlorophenyldiguanido)hexane dihydrochloride in a specific proportion and a naphthiomate type antifungal agent, etc. in polyamide fibers. CONSTITUTION:A naphthiomate type antifungal agent, e.g. 2-naphthyl-N-methyl- N-(3-toluyl)thiocarbamate, or benzimidazole type antifungal agent, e.g. 2-(4- thiazolyl)benzimidazole, or both are incorporated with bis(p-chlorophenyldiguanido)hexane dihydrochloride in an amount of 0.1-0.8 of that of the antifungal agent, and the resultant mixture is blended with polyamide chips. The resultant blend is then melt spun to give the aimed fibers. The amount of the antifungal agent is preferably 0.5-5.0wt%.
INTRODUCTION: Although dolutegravir (DTG) is deemed stable, safe, cost-effective, and clinically beneficial, it also carries the risk of side effects, including observed weight gain among patients on DTG-based antiretroviral therapy (ART) regimens. We compared weight changes among adults (≥18 years) initiating tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) or tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE) regimens and those switching from TEE to TLD (TEE-to-TLD switchers) in three large primary care facilities in South Africa METHODS: We conducted a retrospective longitudinal record review using patient medical records, extracting relevant demographic and clinical data from October 2018 to June 2021 from randomly selected adults who initiated TLD or TEE (initiators) and adult TEE-to-TLD switchers. We assessed weight, body mass index (BMI), and percentage weight changes for both groups and fitted linear regression and generalized linear models to determine factors associated with weight and BMI change and percentage weight change ≥10%, respectively, among treatment initiators. We fitted linear mixed-effect models among TEE-to-TLD switchers to consider repeated measures.
RESULTS: Of 860 initiators, 450 (52.3%) initiated on TEE and 410 (47.7%) on TLD, with median follow-up of 1.4 years and 1.0 year, respectively. At initiation, 43.3% on TEE and 40.8% on TLD were overweight or obese. TLD initiators had an adjusted higher mean weight gain of 1.6 kg (p < 0.001) and mean BMI gain of 0.51 kg/m2 (p < 0.001) than TEE initiators. Independent risk factors for higher mean weight and BMI included age ≥50 years, male, on ART for >12 months, initial BMI of <18.5 kg/m2, and CD4 counts <200 cells/μL. Of 298 TEE-to-TLD switchers, 36.6% were overweight or obese at TEE initiation. Comparing before and after TLD switch, TEE-to-TLD switchers had an adjusted mean weight of 1.2 kg less while on TLD (p = 0.026). Being overweight and CD4 counts >350 cells/μL were independent risk factors for lower weight gain after TLD switch.
CONCLUSIONS: We report more weight gain among TLD than among TEE initiators, although to a lesser extent than previously reported. TEE-to-TLD switchers experienced less weight gain after TLD switch; return to health before receiving TLD may be a contributory factor. The current findings are reassuring for those switching to a DTG-based regimen.
1480089 Diluent composition for diagnostic tests E I DU PONT DE NEMOURS & CO 28 Nov 1974 [29 Nov 1973] 51606/74 Heading G1B [ Also in Division C3] A liquid composition suitable for use as a diluent for a biologically active material e.g. in the diagnostic measurement of enzyme activity, comprises 4À5 to 8À0 g/dl of a bovine albumin 95- 145 meq/l of sodium ions, 90-112 meq/l of chloride ions, 1-4 mg/dl of magnesium ions, 7- 12 mg/dl of calcium ions, 3-5À5 meq/l of potassium ions, up to 4 mg/l of zinc ions, 2-6 mg/dl of phosphorus as phosphate ions and up to 4 mg/dl of sulphur as sulphate ions, in de-ionized water. The pH is typically 6À5-7À5, osmolarity 190-300 milliosmoles, viscosity 1À2-2À0 centipoise and ionic strength 0À11-0À14 Á. The composition may be stored in the form of porous spheres of diameter not exceeding 1 mm and pore volume of at least 90%, which spheres are produced by spraying the liquid composition into boiling dichlorodifluoromethane at -25‹C and freeze-drying the frozen droplets. The porous spheres are dissolved in de-ionized water prior to use. Examples are directed to the comparison of acid or alkaline phosphatase and creatine phosphokinase activities when measured in undiluted human serum and human serum diluted with distilled water, saline solution or the liquid composition of the invention.
BACKGROUND: Cerebral small-vessel disease (cSVD) is the leading monogenic cause of stroke. Despite genetic screening in routine diagnosis, many cases remain without a known causative variant. Using a cohort with suspected familial cSVD and whole-genome sequencing, we screened for variants in genes associated with monogenic cSVD and searched for novel variants associated with the disease.
METHODS AND RESULTS: Rare variants were identified in whole-genome sequencing data from the NBR (National Institute for Health Research BioResource Rare Disease) study. Pathogenic variants in known monogenic cSVD genes were identified. Gene-based burden tests and family analysis were performed to identify novel variants associated with familial cSVD. A total of 257 suspected cSVD cases (mean ± SD age, 56.2 ± 16.1 years), and 13 086 controls with other nonstroke diseases (5874 [44.9%] men) were studied. A total of 8.9% of the cases carried a variant in known cSVD genes. Excluding these known causes, 23.6% of unrelated subjects with cSVD carried predicted deleterious variants in the Genomics England gene panel, but no association was found with cSVD in burden tests. We identified potential associations with cSVD in noncoding genes, including RP4-568F9.3 (adjusted P = 7.1 × 10-25), RP3-466I7.1 (adjusted P = 8.9 × 10-16), and ZNF209P (adjusted P = 1.0 × 10-15), and matrisomal genes (adjusted P = 5.1 × 10-6), including FAM20C, INHA, LAMC1, and VWA5B2.
CONCLUSIONS: Predicted deleterious variants in known cSVD genes were present in 23.6% of unrelated cases with cSVD, but none of the genes were associated with the disease. Rare variants in noncoding and matrisomal genes could potentially contribute to cSVD development. These genes could play a role in tissue development and brain endothelial cell function. However, further studies are needed to confirm their pathophysiological roles.
BACKGROUND AND STUDY AIMS: Colorectal cancer (CRC) may develop from focal changes within benign or precancerous polyps. The immune system's failure to detect and eradicate tumor cells due to immune surveillance evasion, allows cancer to develop and spread. This study aims to analyze the differences in circulating lymphocyte subpopulations in patients with colorectal inflammatory polyps, colorectal adenomas and CRC.
PATIENTS AND METHODS: We retrospectively reviewed patients from September 2016 to December 2019 at the Shaoxing Second Hospital. Using flow cytometry, the subset distribution and immunophenotype of T cells, CD4+ T cells, CD8+ T cells, B cells and NK cells were investigated in peripheral blood mononuclear cell samples. The counts of lymphocytes were determined by white blood cell counts.
RESULTS: In total, 518 patients were included in this study. The counts of lymphocytes, T cells and NK cells in patients with inflammatory polyps, colorectal adenomas and CRC were lower than controls. The counts and percentages of CD8+ T cells in patients with inflammatory polyps, colorectal adenomas and CRC were lower than controls. The counts of CD4+ T cells were lower in patients with CRC than inflammatory polyps. The percentages of CD4+ T cells in patients with inflammatory polyps, colorectal adenomas and CRC were higher than controls, but lower in the CRC than inflammatory polyps, colorectal adenomas. The counts and percentages of B cells were lower in CRC patients than colorectal adenomas patients. In addition, the percentages of B cells were higher in patients with inflammatory polyps and colorectal adenomas than in controls.
CONCLUSIONS: The decrease in counts of lymphocyte, T cells, CD8+ T cells and NK cells in patients may be related to the dysplasia of epithelial cells. Furthermore, the B cells and CD4+ T cells may be related to the malignant growth of the dysplastic epithelial cells.
A phase II open-label multicenter trial evaluating response rate (RR) in patients receiving precision radiation (SBRT) to melanoma metastasis that have progressed on PD-1 inhibitor therapy. Patients will continue on PD-1 inhibitor therapy (pembrolizumab or nivolumab) for up to one year after completed precision radiation and will be followed-up for 24 months or until disease progression or death. The primary endpoint of the study is overall response rate (ORR) in non-irradiated lesions. The study will be conducted according to Simon´s two Stage minimax Design. Patients will be enrolled in two batches, first consisting of 13 patients. If no objective responses (complete response (CR) or partial response (PR)) are reported after the first stage, the study is interrupted early for futility. When the 13th patient is recruited, if there is at least one objective response in patient´s non-irradiated lesion(s), the recruitment can proceed into second stage. 14 more patients will then be included up to a total of 27 patients to determine ORR along with the 95% confidence interval. The test result is considered positive when at least 15% of the patients have a confirmed objective response.
Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
Recent studies indicate that hepatic diseases are associated with psoriasis. Non-invasive tests, including the Fibrosis-4 (FIB-4) index, which can confidently rule out the presence of advanced fibrosis, are currently receiving attention. However, data on the FIB-4 index in psoriasis patients and the effects of biologics on the FIB-4 index are limited. We investigated the relationships between the FIB-4 index and demographic or clinical characteristics as well as the effects of biologics on the FIB-4 index in psoriasis patients. Psoriasis patients aged 36-64 years, whose treatment was initiated with interleukin (IL)-17 inhibitors or IL-23 inhibitors for psoriasis from May 2015 to December 2022, were consecutively included. Data were collected retrospectively from the patients' charts. A total of 171 psoriasis patients were included in this study. Thirty-four, 43, 21, 32, and 41 psoriasis patients were treated with secukinumab, ixekizumab, brodalumab, guselkumab, or risankizumab, respectively. In biologics-naïve patients, a significant but weak positive correlation was observed between the FIB-4 index and age (r = 0.3246, p = 0.0018). There was no significant correlation between the FIB-4 index and other demographic or clinical characteristics. Regarding the effects of biologics on the FIB-4 index, no significant change was observed in psoriasis patients treated with any biologics. However, in psoriasis patients with a baseline FIB-4 index of >1.3, patients treated with guselkumab and those treated with either IL-23 inhibitor showed significantly decreased FIB-4 index scores 6 months after initiating the biologics (p = 0.0323, p = 0.0212). In contrast, no change was observed in FIB-4 index scores in patients treated with IL-17 inhibitors. In conclusion, our study revealed that the FIB-4 index was correlated with age in psoriasis patients. Furthermore, IL-23 inhibitors (but not IL-17 inhibitors) decreased the FIB-4 index score at 6 months in psoriasis patients with elevated FIB-4 index scores at baseline. Further studies are needed to clarify whether IL-23 inhibitors improve liver fibrosis physiologically and functionally.
The invention discloses bergapten liposome, a preparation method thereof, an encapsulation efficiency measuring method, bergapten liposome gel and a preparation method thereof, and belongs to the technical field of medicines. The preparation method of the bergapten liposome comprises the following steps of raw materials of bergapten, egg yolk lecithin, cholesterol and tween 80; the preparation method is a film dispersion method. The method for measuring the encapsulation efficiency of the bergapten liposome adopts a dextran microcolumn centrifugation method for measurement. The invention also discloses bergapten liposome gel which takes the bergapten liposome as a raw material. The invention creatively uses the mixed volatile oil of the frankincense and the myrrh as the penetration enhancer, which not only can promote the drug penetration, but also can play the roles of anti-inflammatory and detumescence. The invention creatively prepares bergapten into liposome external gel, increases bergapten solubility and skin retention, and provides a research foundation for the application of drugs with poor water solubility in vitiligo treatment.
To provide a retarder of anti-cancer agent resistance that is extracted from Termitomyces sp. being a basidiomycete, and that hardly causes acquired resistance, and a cancer therapeutic agent containing the retarder.SOLUTION: A cancer therapeutic agent contains an active ingredient derived from Termitomyces sp.. The active ingredient may be dry powder of an artificially cultured culture solution of Termitomyces sp.. The active ingredient may be alcohol extract from an artificially cultured culture solution of Termitomyces sp.. The active ingredient may be a fruit body or mycelium of Termitomyces sp. extract from alcohol.SELECTED DRAWING: None
Investigators tied a 1-cm surgical suture at the tip of a 16 French silicon NG tube (120 cm long, cost 5 US dollars). One conventional EGD (diameter 2.8 mm) biopsy forceps was inserted into the lumen as a strengthened stylet. Then investigators inserted a biopsy forceps (diameter 2.0 mm) and protruded a little out of the working channel of an ultrathin EGD scope (Fujinon EG 530 N, diameter 5.9 mm) to grasp the suture. The ultrathin EGD and NG tube were parallelly pushed into a selected nostril after adequate decongestive anesthesia (Epinephrine 0.3% + Lidocaine 5%) into the small intestine as deep as possible to the jejunum.

Being placed to the small intestine as far as possible, the NG tube was released and the ultrathin EGD scope withdrew. When the scope was pulled backwards from the stomach, the shape/layout of a NG-tube could be simultaneously monitored and adjusted. At last, the EGD biopsy forceps (2.8 mm) inside the NG tube was removed. With this method, in real life, a plain film is not necessary to confirm the NG tube position. However, for study purpose, a KUB film was taken to check the NG tube position.
BACKGROUND: Urinary incontinence is a common complication following a stroke. No specific drugs are available in Western medicine, and surgical treatment is highly traumatic, limiting its clinical application. This study aimed to observe the clinical efficacy of electroacupuncture at the "Sacral Four Points" combined with moxibustion at the "Abdominal Three Points" on post-stroke urinary incontinence, exploring its impact on urodynamics and quality of life.
METHODS: Patients with post-stroke urinary incontinence treated at our Hospital from January 2021 to December 2023 were recruited. The study included 117 patients: 57 in the electroacupuncture group and 60 in the combined group. Urodynamic parameters were measured, and scores from the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) and the Incontinence Quality of Life Questionnaire (I-QOL) were recorded before, and after the first and third courses of treatment. Clinical efficacy and adverse reactions were evaluated post-treatment.
RESULTS: The study found no significant differences in clinical characteristics between the groups (p > 0.05), providing a baseline for comparison. Both groups showed substantial decreases in leakage volume after one course of treatment (p < 0.05), with a reduction in the ICIQ-UI SF score (p < 0.05) and an increase in the I-QOL score (p < 0.05). After three courses of treatment, the leakage volume of patients in both groups significantly decreased (p < 0.05), the ICIQ-UI SF score decreased (p < 0.05), and the I-QOL score increased (p < 0.05). The combined group showed a lower leakage volume compared to the electroacupuncture group (p < 0.05), with lower ICIQ-UI SF scores (p = 0.027) and higher I-QOL scores (p = 0.048). Importantly, the total effective rate was significantly higher in the combined group (88.33% vs 64.91%, p = 0.037), demonstrating the safety and efficacy of the treatment.
CONCLUSIONS: Electroacupuncture at the "Sacral Four Points" combined with moxibustion at the "Abdominal Three Points" improves the clinical symptoms and enhances the quality of life for patients with post-stroke urinary incontinence, showing superior results compared to electroacupuncture alone.
FIELD: medicine. ^ SUBSTANCE: inventions relate to cosmetic industry. Method for application of disperse useful agent onto hair. Composition for personal hygiene. Two-block conjugate on the basis of peptides for use in composition. Three-block conjugate on the basis of peptides for use in composition. Peptide getting bound with polymethylmethacrylate for use in composition. ^ EFFECT: compositions increase duration of binding of disperse useful agent with body surface. ^ 42 cl, 29 dwg, 18 tbl, 22 ex
Targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), however acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutations and (or) upregulation of signaling downstream of EGFR/HER2 to Akt and (or) mitogen activated protein kinase (MAPK) pathways. However, additional pathways of resistance may exist thus, confounding successful therapy. To determine novel mechanisms of EGFR/HER2 therapy resistance in breast cancer, Gefitinib® or Lapatinib® resistant variants were created from SKBR3 breast cancer cells. Syngenic therapy sensitive and resistant SKBR3 variants were characterized for mechanisms of resistance by mammosphere assays, viability assays, and western blotting for total and phospho proteins. Combinations of treatments focused on RGFR/HER2 and Rac inhibitors (1,5-disubstituted 1, 2, 3-triazoles, e.g. Ehop-16 and MBQ-167) are proposed as viable strategies for treatment of EGFR/HER2 targeted therapy resistant breast cancer.
PURPOSE:To provide an antitumor agent containing descarboxyl-desdimethyl- quadrone as an active component. CONSTITUTION:The objective antitumor agent can be prepared by using the compound of formula I as an active component. The compound exhibits higher antitumor activity than conventional quadronemimic compounds, and can by synthesized easily from the compound of formula II according to the reaction formula. It can be administered orally or parenterally, in the form of powder, granule, tablet, capsule, etc. for oral administration, or injection, instillation suppository, etc. for parenteral administration. Dose: 10-500mg daily.
Upon enrollment, subjects in SMTB group and Brace group were all prescribed a brace with reference to the 2016 SOSORT guidelines and received preliminary assessment for brace design and fabrication at their first visit. Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
The formation of inhibitors (neutralizing antibodies) to Factor IX has occurred following REBINYN. If expected plasma factor IX activity levels are not attained, or if bleeding is not controlled as expected with the administered dose, perform an assay that measures Factor IX inhibitor concentration. Monitor all patients using clinical observations and laboratory tests for the development of inhibitors [see Warnings and Precautions (5.5)]. 

An association between the development of Factor IX inhibitors and allergic reactions has been reported. Evaluate patients experiencing allergic reactions for the presence of an inhibitor. Patients with Factor IX inhibitors may be at an increased risk of severe allergic reactions with subsequent exposure to Factor IX.